发明名称 |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) AND INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
摘要 |
The present invention relate to antisense oligonucleotides that modulate the expression of and/or function of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TFE3 and/or IRS2. |
申请公布号 |
US2015080455(A1) |
申请公布日期 |
2015.03.19 |
申请号 |
US201414516008 |
申请日期 |
2014.10.16 |
申请人 |
CuRNA, Inc. |
发明人 |
COLLARD Joseph;Khorkova Sherman Olga |
分类号 |
C12N15/113;C12Q1/68 |
主分类号 |
C12N15/113 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of modulating a function of and/or the expression of an Insulin Receptor Substrate 2 (IRS2) and/or Transcription factor E3 (TFE3)Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 497 of SEQ ID NO: 3 thereby modulating a function of and/or the expression of the Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotide in patient cells or tissues in vivo or in vitro. |
地址 |
Miami FL US |